Umbilical cord blood transplantation (CBT) from unrelated donors has increased recently for adult patients with hematological diseases who have no other suitable related or unrelated donors, as cord blood (CB) shows clinical characteristics, such as greater availability, shorter time for donor searches and less stringent requirements for HLA compatibility. [1] [2] [3] [4] However, primary graft failure or delayed neutrophil recovery are often encountered as significant problems. [1] [2] [3] [4] As the existence of HLA antibody has been thought to increase the risk of graft failure, patients with HLA antibodies may be excluded as candidates for CBT. 3 Such patients also tend to be excluded as candidates for CBT because of the need for HLAmatched platelet transfusion. However, few reports have described the practical impact of HLA antibody in CBT. 5, 6 Here, we report two cases of successful engraftment following CBT for patients with HLA antibodies (Table 1) .
Case 1
The first case involved a 20-year-old woman with ALL in non-remission state. Although she was found to have HLA antibodies against HLA-B13, she underwent CBT from an unrelated female donor in March 2008, as she had no HLA-matched BM donors in her family, and the situation allowed no delay for the search process from the Japan Marrow Donor Program. The donor displayed two antigen mismatches to the patient, in HLA-B and DR. Numbers of total nucleated cells and CD34-positive cells transfused were 2.81 Â 10 7 /kg and 1.22 Â 10 5 /kg, respectively. The conditioning regimen included 12 Gy TBI, 12 g/m 2 cytarabine and 120 mg/kg CY. GVHD prophylaxis comprised CYA and short-term MTX. Recombinant human G-CSF was administered i.v. at 5 mg/kg/day from day 1 after CBT to facilitate neutrophil engraftment, and a neutrophil count consistently above 0.5 Â 10 9 /l was achieved on day 19. A reticulocyte percentage above 1 and a platelet count above 50 Â 10 9 /l were observed on days 24 and 30, respectively. Grade III acute GVHD involving the gastrointestinal tract occurred and steroid therapy, including steroid pulse therapy, was initiated on day 35. Complete donor chimerism of BM mononuclear cells was confirmed using PCR methods on day 35, and the patient remained in remission until the last follow-up evaluation on day 149. She died on day 161 from thrombotic microangiopathy, probably due to GVHD and subsequent multiple organ failure.
Case 2
The second case involved a 33-year-old woman with acute myeloblastic leukemia in the first relapse. Her situation was considered refractory to platelet transfusion due to HLA antibodies after she received the reinduction therapy following the first relapse. HLA antibodies were identified against HLA-A2, one of the donor-specific antigens in the host-versus-graft reaction. 6 U/day from day 1 after CBT to facilitate neutrophil engraftment. A neutrophil count consistently above 0.5 Â 10 9 /l was achieved on day 35. A reticulocyte percentage above 1% was observed on day 33. Platelet recovery was not achieved during the follow-up period. Grade II acute GVHD occurred, but resolved without any additional immunosuppressant. Complete donor chimerism of BM mononuclear cells was confirmed by PCR methods on day 35, and the patient remained in remission until the last follow-up evaluation on day 100.
The presence of HLA antibody may be considered as a contraindication for CBT due to associated poor engraftment. 3 Kataoka et al. 5 previously reported two cases of successful engraftment following CBT for patients with HLA antibodies without corresponding HLA in the transplanted CB. However, case 2 in our report displayed HLA antibodies directed against the HLA present on the transplanted CB. This represents the first case to be reported from this perspective. Takanashi et al. 6 found no significant differences in Kaplan-Meier estimates of engraftment between recipients with or without HLA antibodies, but successful engraftment was achieved in only four of the eight recipients in whom the specificity of HLA antibody was directed against the HLA present on transplanted CB. As the average number of total CD34-positive cells in those four cases was 0.58 Â 10 5 /kg, the hematopoietic progenitor content may be important for engraftment, particularly in cases with HLA antibody directed against HLA present on the transplanted CB.
In conclusion, the existence of HLA antibodies cannot be considered as a reason to avoid CBT. Although more cases are needed to clarify issues of tolerability, even cases with HLA antibody and the corresponding HLA in the proposed CB may not be contraindicated for CBT based on our cases. 
